Oral Flucytosine is the Safest Oral Antifungal for Yeast UTI in Patients with Prolonged QT
For a patient with prolonged QT interval and a yeast urinary tract infection, oral flucytosine 25 mg/kg four times daily for 7-10 days (cystitis) or 2 weeks (pyelonephritis) is the preferred oral antifungal agent, as it avoids the QT-prolonging effects of azole antifungals while achieving excellent urinary concentrations.
The QT Prolongation Problem with Standard Therapy
Fluconazole is typically the first-line oral agent for Candida UTIs according to IDSA guidelines 1. However, all azole antifungals (fluconazole, voriconazole, itraconazole, posaconazole) are associated with QT interval prolongation and risk of torsades de pointes (TdP) 2, 3. In a 2024 case series, 63% of azole-related QTc prolongation cases involved fluconazole, with 81% of patients developing TdP 2. Women and elderly patients face particularly elevated risk 4, 2.
The Flucytosine Solution
The IDSA guidelines explicitly recommend oral flucytosine as an alternative for fluconazole-resistant organisms 1:
- For cystitis: Oral flucytosine 25 mg/kg four times daily for 7-10 days (strong recommendation) 1
- For pyelonephritis: Oral flucytosine 25 mg/kg four times daily for 2 weeks (weak recommendation for monotherapy) 1
Flucytosine achieves excellent urinary concentrations and has broad activity against Candida species without QT-prolonging effects 5. This makes it uniquely suited for patients with baseline QT prolongation.
Critical Caveats with Flucytosine
- Monitor for bone marrow toxicity: Check CBC and hepatic/renal function regularly, as flucytosine can cause myelosuppression and hepatotoxicity
- Dose adjustment required for renal impairment: Essential given urinary excretion
- Resistance can develop with monotherapy: More common with prolonged use, but acceptable for standard 7-14 day UTI treatment courses
- Ensure fluconazole susceptibility is confirmed: If organism is fluconazole-susceptible but you cannot use fluconazole due to QT concerns, flucytosine remains appropriate
Alternative: Amphotericin B Deoxycholate (Non-Oral)
If oral therapy is absolutely required but flucytosine is unavailable or contraindicated, you must use intravenous amphotericin B deoxycholate 0.3-0.6 mg/kg daily 1. Amphotericin does not prolong QT interval 3 but requires IV administration and has significant nephrotoxicity risk.
What About Echinocandins?
Echinocandins (caspofungin, micafungin, anidulafungin) do not achieve adequate urinary concentrations and should not be used for UTIs 6, 5. They are only appropriate for candidemia or disseminated candidiasis, not isolated urinary tract infections.
Risk Stratification for Your Patient
Before initiating any therapy, assess:
- Current QTc value: Risk substantially increases when QTc >500 ms or when drugs increase QTc by >60-70 ms 4
- Concurrent QT-prolonging medications: Common culprits include antidepressants (especially citalopram/escitalopram), antipsychotics, macrolide antibiotics, and antiarrhythmics 4
- Electrolyte status: Hypokalemia, hypomagnesemia, and hypocalcemia amplify TdP risk 4, 3
- Structural heart disease: Increases baseline arrhythmia susceptibility 4, 3
Management Algorithm
- Confirm symptomatic UTI: Remove catheter if present (strong recommendation) 1
- Obtain susceptibilities: Identify Candida species and fluconazole susceptibility
- Check baseline QTc and electrolytes
- For fluconazole-susceptible organisms with prolonged QT:
- First choice: Oral flucytosine 25 mg/kg QID for 7-10 days (cystitis) or 14 days (pyelonephritis)
- Alternative: IV amphotericin B deoxycholate 0.3-0.6 mg/kg daily
- For fluconazole-resistant C. glabrata or C. krusei: Amphotericin B deoxycholate is mandatory regardless 1
Common Pitfall to Avoid
Do not assume asymptomatic candiduria requires treatment 1, 6. Most candiduria represents colonization. Only treat if the patient has symptoms, is neutropenic, is a very low-birth-weight infant, or will undergo urologic procedures 1.